RNA-Biopolymer Nanostructures for Smart Insulin Delivery

Information

  • Research Project
  • 6991706
  • ApplicationId
    6991706
  • Core Project Number
    R43DK072774
  • Full Project Number
    1R43DK072774-01
  • Serial Number
    72774
  • FOA Number
    PA-02-25
  • Sub Project Id
  • Project Start Date
    9/1/2005 - 19 years ago
  • Project End Date
    8/31/2006 - 18 years ago
  • Program Officer Name
    ARREAZA-RUBIN, GUILLERMO
  • Budget Start Date
    9/1/2005 - 19 years ago
  • Budget End Date
    8/31/2006 - 18 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/29/2005 - 19 years ago
Organizations

RNA-Biopolymer Nanostructures for Smart Insulin Delivery

DESCRIPTION (provided by applicant): SmartCells has developed Smartlnsulin, a once-a-day, injectable formulation of insulin for the treatment of diabetes. True glycemic control requires treatments that provide plasma glucose-regulated insulin replacement. Smartlnsulin, which senses and responds to altered serum glucose levels in a clinically relevant way, directly addresses this need. Unlike pump- and cell-based systems, Smartlnsulin is a "smart" nanostructured material that self-assembles from two biomolecular building blocks: a glycosylated insulin polymer conjugate (IPC) and a multimeric glucose-binding molecule (GBM). In this proposal, we seek to replace our proof-of-concept formulation with a safer, non-immunogenic, synthetic GBM constructed from ribonucleic acid (RNA)-based aptamers through the following specific aims: -Develop nuclease-resistant RNA-based aptamers that bind glucose -Synthesize multimeric RNA aptamers from monomeric constructs using a self-assembly process -Demonstrate that RNA aptamers form gels with IPCs and dissolve at physiologically relevant glucose concentrations. The impacts on public health as a result of this project are potentially significant. Poor glycemic control has been shown to cause a host of diabetic complications including retinopathy, neuropathy, nephropathy, and increased prevalence of heart disease and stroke, which result in over $54 billion annually in medical costs. The landmark Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS), have clinically proven that tighter glycemic control, as measured by lower glycosylated hemoglobin A1c (HbA1c) levels, significantly reduces the incidence of these complications. Thus, Smartlnsulin seeks to provide tighter glycemic control, lowered HbA1c levels, and decreased incidence of diabetic complications.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    195241
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:195241\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SMARTCELLS, INC.
  • Organization Department
  • Organization DUNS
    143319973
  • Organization City
    BEVERLY
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01951
  • Organization District
    UNITED STATES